Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Study Focuses on Outpatient CAR T-Cell Therapy in Multiple Myeloma
July 20th 2024Taiga Nishihori, MD, discusses a study in which investigators evaluated patients with relapsed/refractory multiple myeloma who were hospitalized and treated with commercial ciltacabtagene autoleucel at Moffitt Cancer Center between May 2022 and May 2023.
Watch
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Study Shows First Evidence of Effective Systemic Therapy for HER2+ Breast Cancer With LM
July 16th 2024Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastases in patients with HER2-positive breast cancer.
Watch
Jabbour Covers the FDA Approval of Ponatinib Plus Chemo in Ph+ ALL
July 15th 2024Elias Jabbour, MD, provides an overview of the significance of the FDA approval of ponatinib plus chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Watch
Expanding Treatment Options in Urothelial Cancer With ADCs
July 12th 2024Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the potential benefits of antibody-drug conjugates in urothelial cancer while acknowledging the need for more education and experience among physicians to optimize their use.
Watch
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More
Real-World Findings on TLS Prevention and Management With Venetoclax in CLL
July 8th 2024Mark Geyer, MD, and Yannis K. Valtis, MD, delved into the background and findings from a study looking at clinical and laboratory tumor lysis syndrome in patients with CLL who were treated with venetoclax in the inpatient and outpatient settings.
Read More
Real-World Study Confirms Lenvatinib's Benefit in RAI-Refractory DTC
July 3rd 2024In an interview with Targeted Oncology, Francis P. Worden, MD, delved into the rationale behind the study and the implications of this research for patients with radioidine-refractory differentiated thyroid cancer.
Read More
Novel Therapy Boosts Survival After Stem Cell Transplants
July 3rd 2024Alexandra Gomez Arteaga, MD, discussed findings from a retrospective study comparing Orca-T with posttransplant cyclophosphamide graft-vs-host disease prophylaxis to assess outcomes in patients undergoing hematopoietic cell transplant.
Read More
Ghia Highlights 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
July 1st 2024Paolo Ghia, MD, PhD, discusses the key takeaways from 5-year data follow-up data from the phase 2 CAPTIVATE trial of ibrutinib plus venetoclax for the treatment of patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma.
Watch